RxDoctor Payments Data

Rebecca Cooksley

Family · Lincoln, NENPI 1700400512

Payments from drug & device makers

$3,071in general payments, 2019–2025

Across 163 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$313
  • Bayer$293
  • Otsuka America Pharmaceutical, Inc.$244
  • Astellas Pharma US Inc$150
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
  • plus $739 from 21 others

What the payments were for

  • Food & beverage$3,071100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,071 in reported general payments places this provider in the 90th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,468
Medicare patients
42
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$48,780
OzempicSemaglutide24$46,004
RybelsusSemaglutide23$22,741
FarxigaDapagliflozin Propanediol25$21,244
JanuviaSitagliptin Phosphate18$17,132
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$14,421
Bevespi AerosphereGlycopyrrolate/Formoterol Fum23$10,423
Tresiba Flextouch U-200Insulin Degludec16$10,383
Repatha SureclickEvolocumab15$9,597
SymbicortBudesonide/Formoterol Fumarate36$7,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,265
Combivent RespimatIpratropium/Albuterol Sulfate15$7,218
Albuterol Sulfate HfaAlbuterol Sulfate115$3,164
Atorvastatin Calcium275$3,009
Omeprazole134$2,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$313$68,74547 claims
GSKAnoro Ellipta, Trelegy Ellipta$44$21,68641 claims
AbbVieSynthroid$1,245$81613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Nebraska.

Other family in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →